Bipolar Disorder and Attention-Deficit/Hyperactivity Disorder Comorbidity in Children and Adolescents: Evidence-Based Approach to Diagnosis and Treatment

2013 ◽  
Vol 74 (06) ◽  
pp. 628-629 ◽  
Author(s):  
Shefali Miller ◽  
Kiki D. Chang ◽  
Terence A. Ketter
2009 ◽  
Vol 70 (5) ◽  
pp. 756-764 ◽  
Author(s):  
Silzá Tramontina ◽  
Cristian P. Zeni ◽  
Carla R. Ketzer ◽  
Gabriel F. Pheula ◽  
Joana Narvaez ◽  
...  

CNS Spectrums ◽  
2007 ◽  
Vol 12 (10) ◽  
pp. 758-762 ◽  
Author(s):  
Silzá Tramontina ◽  
Cristian Patrick Zeni ◽  
Gabriel Ferreira Pheula ◽  
Carla Ketzer de Souza ◽  
Luis Augusto Rohde

ABSTRACTIntroductionJuvenile bipolar disorder (JBD) is a highly impairing chronic mental health condition that affects children and adolescents' overall functioning. Comorbidity with attention-deficit/hyperactivity disorder (ADHD) is extremely prevalent and may determine worse response to treatment. Few investigations have addressed the use of recent atypical antipsychotics in JBD, although several guidelines suggest their use.MethodsWe conducted a 6-week open trial with aripiprazole in 10 children and adolescents with JBD comorbid with ADHD to assess impact on mania and ADHD symptoms, respectively, by means of the Young Mania Rating Scale and the Swanson, Nolan and Pelham Scale, as well as on global functioning (Clinical Global Impressions–Severity), and adverse events.ResultsSignificant improvement in global functioning scores (F=3.17, P=.01, effect size=0.55), manic symptoms (F=5.63, P<.01; ES=0.93), and ADHD symptoms (t=3.42, P<.01; ES=1.05) were detected. Although an overall positive tolerability was reported, significant weight gain (F=3.07, P=.05) was observed.ConclusionAripiprazole was effective in improving mania and ADHD symptoms, but neither JBD nor ADHD symptom remission was observed in most of the cases. Randomized placebo-controlled trials for JBD and ADHD are needed.


Sign in / Sign up

Export Citation Format

Share Document